Biocept prices IPO at $10, the low end of the range

By
A A A

Biocept, which develops and markets cancer diagnostic tests, raised $19 million by offering 1.9 million shares at $10, the low end of the range of $10 to $12. The company had originally filed to offer 1.8 million shares. At the IPO price, the company commands a market cap of $48 million, which is below our market cap requirement of $50 million. As such, the deal has been excluded from our IPO stats. Biocept plans to list on the NASDAQ under the symbol BIOC. Aegis Capital acted as the lead manager on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: BIOC

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

89,070,840
  • $17.26 ▲ 3.23%
78,931,485
  • $7.02 ▲ 4.46%
77,555,734
  • $6.70 ▲ 6.69%
77,025,346
  • $24.66 ▲ 0.69%
74,713,335
  • $101.80 ▲ 1.82%
72,324,726
  • $7.64 ▲ 0.79%
57,112,188
  • $17.84 ▲ 55.27%
53,321,397
  • $18.01 ▼ 4.46%
As of 12/17/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com